^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Lynozyfic (linvoseltamab-gcpt)
i
Other names: REGN5458, REGN 5458, BCMAxCD3 antibody, BCMAxCD3 bispecific antibody
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Regeneron, Sanofi
Drug class:
CD3 agonist, BCMA inhibitor
Related drugs:
1m
LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
P3, N=915, Not yet recruiting, Regeneron Pharmaceuticals
New P3 trial
|
bortezomib • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
2ms
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) (clinicaltrials.gov)
P2, N=34, Not yet recruiting, Medical College of Wisconsin | Initiation date: Sep 2025 --> Dec 2025
Trial initiation date
|
Lynozyfic (linvoseltamab-gcpt)
3ms
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=30, Not yet recruiting, Fred Hutchinson Cancer Center
New P1/2 trial
|
Lynozyfic (linvoseltamab-gcpt)
3ms
LINKER-MM1: Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=387, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jun 2032 --> Jun 2033 | Trial primary completion date: May 2032 --> Mar 2033
Trial completion date • Trial primary completion date
|
Lynozyfic (linvoseltamab-gcpt)
5ms
Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
P2, N=300, Not yet recruiting, Multiple Myeloma Research Consortium
New P2 trial
|
clonoSEQ
|
Sarclisa (isatuximab-irfc) • Lynozyfic (linvoseltamab-gcpt)
6ms
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) (clinicaltrials.gov)
P2, N=34, Not yet recruiting, Medical College of Wisconsin
New P2 trial
|
Lynozyfic (linvoseltamab-gcpt)
6ms
LINKER-MM2: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments (clinicaltrials.gov)
P1, N=317, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jan 2033 --> Sep 2034 | Trial primary completion date: Mar 2027 --> Apr 2028
Trial completion date • Trial primary completion date
|
lenalidomide • bortezomib • Libtayo (cemiplimab-rwlc) • carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Ogsiveo (nirogacestat) • fianlimab (REGN3767) • Lynozyfic (linvoseltamab-gcpt) • cevostamab (RG6160)
7ms
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy (clinicaltrials.gov)
P1, N=6, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Oct 2025 --> Mar 2028 | Trial primary completion date: Oct 2025 --> Mar 2028
Trial completion date • Trial primary completion date
|
Dupixent (dupilumab) • Lynozyfic (linvoseltamab-gcpt)
8ms
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant (clinicaltrials.gov)
P3, N=1000, Not yet recruiting, European Myeloma Network B.V.
New P3 trial
|
lenalidomide • Darzalex (daratumumab) • Lynozyfic (linvoseltamab-gcpt)
10ms
LINKER-MM3: A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P3, N=380, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Dec 2032 --> Apr 2033 | Trial primary completion date: Dec 2032 --> Apr 2033
Trial completion date • Trial primary completion date
|
pomalidomide • Empliciti (elotuzumab) • Lynozyfic (linvoseltamab-gcpt)
11ms
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=186, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
Lynozyfic (linvoseltamab-gcpt)
1year
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
P1/2, N=186, Not yet recruiting, Regeneron Pharmaceuticals
New P1/2 trial
|
Lynozyfic (linvoseltamab-gcpt)
Share via
